Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, invites to a webcast presentation of its fourth quarter 2024 results, ...
The Board of Directors of Cint Group AB (publ) ("Cint" or the "Company") has today resolved on a new three-year strategy plan ("Cint 2.0") and new financial targets. Cint also announces preliminary fi ...
BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has approved BioArctic's partner Eisai's ...